Harmony Biosciences Holdings (HRMY) Accumulated Expenses (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Accumulated Expenses data on file, last reported at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 17.24% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (down 17.24% YoY), and the FY2025 full-year result was $12.2 million, down 35.06% from the prior year.
• Accumulated Expenses fell to $1.9 million in Q1 2026, from $12.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $99.5 million in Q4 2023 to a low of $1.6 million in Q2 2022.
• A 5-year average of $14.0 million and a median of $7.3 million in 2024 frame the typical range for Accumulated Expenses.
• Peak annual rise in Accumulated Expenses reached 2927.81% in 2023, while the deepest fall reached 90.27% in 2023.
• Tracing HRMY's Accumulated Expenses over 5 years: stood at $3.3 million in 2022, then jumped by 2927.81% to $99.5 million in 2023, then sank by 81.13% to $18.8 million in 2024, then plunged by 35.06% to $12.2 million in 2025, then sank by 84.34% to $1.9 million in 2026.
• Business Quant data shows HRMY's Accumulated Expenses at $1.9 million in Q1 2026, $12.2 million in Q4 2025, and $2.3 million in Q3 2025.